Mayo Clinic researchers used milk-based nanoparticles to deliver siRNA into bile duct cancer cells. This targeted therapy ...

Mayo Clinic researchers have developed a promising new way to deliver treatment directly to cholangiocarcinoma tumors, a rare and aggressive bile duct cancer with limited treatment options, using milk ...

Mayo Clinic researchers have developed a promising new way to deliver treatment directly to cholangiocarcinoma tumors, a rare ...

Colorectal cancer is the top cancer killer for Americans under 50. A 5K race promotes early screening and awareness.

The findings, published in JHEP Reports, point to a potential targeted genetic therapy designed to attack cancer cells while ...

Background High serum levels of interleukin 6 (IL-6) predict poor prognosis in intrahepatic cholangiocarcinoma (iCCA), a malignancy that often develops in a chronically inflamed milieu . Here, tumour ...

An update from Sino Biopharmaceutical ( (HK:1177)) is now available. Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has reported positive Phase III results for TQB3454, an IDH1 inhibitor ...

Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced ...

Pancreatic cancer survivor Pamela Deasy tells Helen O’Callaghan about the moment she received her shattering diagnosis — how hope was all she had to cling to, how determination got her through. And th ...

Givastomig is designed to simultaneously target CLDN18.2 and 4-1BB. CLDN18.2 is a tight junction protein that is typically ...

Four presentations deliver new insights into zanidatamab, including its differentiated HER2 biologyVANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biot ...

The EU approval of Imfinzi for early-stage gastric and gastroesophageal cancers expands the label of one of the company’s top-selling oncology medicines.